Tacrolimus causes a blockage of protein secretion which reinforces its immunosuppressive activity and also explains some of its toxic side-effects

Transplant Immunology

Volumn 22, Issue 1-2, 2009, Pages 72-81

  Rauch, M C ^a   San Martin A ^a   Ojeda, D ^a   Quezada, C ^a   Salas, M ^a   Carcamo J G ^a   Yanez A J ^a   Slebe, J C ^a   Claude, A ^a  

^a UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

Brefeldin A; FK506; Immunosuppressive side effects; Jurkat cells; MIN6 cells; Secretory pathway; Tacrolimus

Indexed keywords

BREFELDIN A; CYCLOSPORIN A; GLUCOSE; INTERLEUKIN 2; PHORBOL 13 ACETATE 12 MYRISTATE; PHYTOHEMAGGLUTININ; TACROLIMUS;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETOGENESIS; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

ANIMALS; BREFELDIN A; CELL LINE, TUMOR; GENE EXPRESSION; GLUCOSE; GOLGI APPARATUS; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; PHYTOHEMAGGLUTININS; PROTEINS; SECRETORY PATHWAY; T-LYMPHOCYTES; TACROLIMUS; TETRADECANOYLPHORBOL ACETATE;

EID: 70449519056     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2009.07.001     Document Type: Article

References (96)

1. Yocum D.E., Furst D.E., Kaine J.L., Baldassare A.R., Stevenson J.T., Borton M.A., et al. Tcrolimus Rheumatoid Arthritis Study Group. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 48 12 (2003) 3328-3337
2. Kitahara K., and Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol 19 3 (2007) 238-245
3. Roehrl M.H., Kang S., Aramburu J., Wagner G., Rao A., and Hogan P. Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules. Proc Natl Acad Sci U S A 101 20 (2004) 7554-7559
4. Miyata S., Ohkubo Y., and Mutoh S. A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res 54 1 (2005) 1-9
5. Sigal N.H., Dumont F.J., and Cyclosporin A. FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Annu Rev Immunol 10 (1992) 519-560
6. Schreiber S.L. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251 4991 (1991) 283-287
7. Griffith J.P., Kim J.L., Kim E.E., Sintchak M.D., Thomson J.A., Fitzgibbon M.J., et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82 3 (1995) 507-522
8. Kaye R.E., Fruman D.A., Bierer B.E., Albers M.W., Zydowsky L.D., Ho S.I., et al. Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12. Proc Natl Acad Sci U S A 89 18 (1992) 8542-8546
9. Liu J., Farmer Jr. J.D., Lane W.S., Friedman J., Weissman I., and Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 4 (1991) 807-815
10. Clipstone N.A., Fiorentino D.F., and Crabtree G.R. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. J Biol Chem 269 42 (1994) 26431-26437
11. Timmerman L.A., Clipstone N.A., Ho S.N., Northrop J.P., and Crabtree G.R. Rapid shuttling of NF-AT in discrimination of Ca21 signals and immunosuppression. Nature 383 6603 (1996) 837-840
12. Clipstone N.A., and Crabtree G.R. Calcineurin is a key signalling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506. Ann N Y Acad Sci 696 (1993) 20-30
13. Hanke J.H., Nichols L.N., and Coon M.E. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. Lymphokine Cytokine Res 11 5 (1992) 221-231
14. Wang S.C., Jordan M.L., Tweardy D.J., Wright J., Hoffman R.A., and Simmons R.L. FK-506 inhibits proliferation and IL-4 messenger RNA production by a T-helper 2 cell line. J Surg Res 53 2 (1992) 199-202
15. Tocci M.J., Matkovich D.A., Collier K.A., Kwok P., Dumont F., Lin S., et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 143 2 (1989) 718-726
16. Kino T., Inamura N., Sakai F., Nakahara K., Goto T., Okuhara M., et al. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 19 5 Suppl 6 (1987) 36-39
17. Haddad E.M., McAlister C., Renouf E., Malthaner R., Kjaer M.S., and Gluud L.L. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 18 4 (2006) CD005161
18. Fischereder M., and Kretzler M. New immunosuppressive strategies in renal transplant recipients. J Nephrol 17 1 (2004) 9-18
19. Drachenberg C.B., Klassen D.K., Weir M.R., Wiland A., Fink J.C., Bartlett S.T., et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation 68 3 (1999) 396-402
20. Wijdicks E.F.M., Wiesner R.H., and Krom R.A.F. Neurotoxicity in liver transplant recipients with cyclosporin immunosuppression. Neurology 45 11 (1995) 1962-1964
21. Wijdicks E.F.M., Dahlke L.J., and Wiesner R.H. Oral cyclosporin decreases severity of neurotoxicity in liver transplant recipients. Neurology 52 8 (1999) 1708-1710
22. Wong M., Mallory Jr. G.B., Goldstein J., Goyal M., and Yamada K.A. Neurologic complications of pediatric lung transplantation. Neurology 53 7 (1999) 1542-1549
23. Jain A., Brody D., Hamad I., Rishi N., Kanal E., and Fung J. Conversion to Neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. Transplantation 69 1 (2000) 172-176
24. Penfornis A., and Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 32 5 Pt 2 (2006) 539-546
25. Cosio F.G., Pesarento T.E., Osei K., Henry M.L., and Ferguson R.M. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipient transplanted in recent years. Kidney Int 59 2 (2001) 732-737
26. Pirsch J.D., Miller J., Deierhoi M.H., Vincenti F., and Filo R.S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 63 7 (1997) 977-983
27. Fuhrer D.K., Kobayashi M., and Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 3 6 (2001) 393-402
28. Paty B.W., Harmon J.S., Marsh C.L., and Robertson R.P. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 73 3 (2002) 353-357
29. Bell E., Cao X., Moibi J.A., Greene S.R., Young R., Trucco M., et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52 11 (2003) 2731-2739
30. Polastri L., Galbiati F., Bertuzzi F., Fiorina P., Nano R., Gregori S., et al. Secretory defects induced by immunosuppressive agents on human pancreatic beta-cells. Acta Diabetol 39 4 (2002) 229-2233
31. Hui H., Khoury N., Zhao X., Balkir L., D'Amico E., Bullotta A., et al. Adenovirus-mediated XIAP gene transfer reverses the negative effects of immunosuppressive drugs on insulin secretion and cell viability of isolated human islets. Diabetes 54 2 (2005) 424-433
32. Nir T., Melton D.A., and Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 117 9 (2007) 2553-2561
33. Hirano Y., Fujihira S., Ohara K., Katsuki S., and Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 53 4 (1992) 889-894
34. Hirano Y., Mitamura T., Tamura T., Ohara K., Mine Y., and Noguchi H. Mechanism of FK506-induced glucose intolerance in rats. J Toxicol Sci 19 2 (1994) 61-65
35. Strasser S., Alejandro R., Shapiro E.T., Ricordi C., Todo S., and Mintz D.H. Effect of FK506 on insulin secretion in normal dogs. Metab Clin Exp 41 1 (1992) 64-67
36. Ericzon B.G., Wijnen R.M.H., Kubota K., Kootstra G., and Groth C.G. FK506-induced impairment of glucose metabolism in the primate. Studies in pancreatic transplant recipients and in nontransplanted animals. Transplantation 54 4 (1992) 615-620
37. Ericzon B.G., Wijnen R.M.H., Tiebosch A., Kubota K., Kootstra G., and Groth C.G. The effect of FK506 treatment on pancreatic duodenal allotransplantation in the primate. Transplantation 53 6 (1992) 1184-1189
38. Tamura K., Fujimura T., Tsutsumi T., Nakamura K., Ogawa T., Atumaru C., et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic b-cell. Transplantation 59 11 (1995) 1606-1613
39. Larsen J.L., Bennett R.G., Burkman T., Ramirez A.L., Yamamoto S., Gulizia J., et al. Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats. Transplantation 82 4 (2006) 466-470
40. Muraoka K.I., Fujimoto K., Sun X., Yoshioka K., Shimizu K.I., Yagi M., et al. Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-K{green}B. J Clin Invest 97 11 (1996) 2433-2439
41. Manthey K.C., Griffin J.B., and Zempleni J. Biotin supply affects expression of biotin transporters, biotinylation of carboxylases, and metabolism of interleukin-2 in Jurkat cells. J Nutr 132 5 (2002) 887-892
42. Zempleni J., and Mock D.M. Uptake and metabolism of biotin by human peripheral blood mononuclear cells. Am J Physiol Cell Physiol 275 2 Pt 1 (1998) C382-C388
43. Rauch M.C., Brito M., Zambrano A., Espinoza M., Pérez M., Yañez A., et al. Differential signaling for enhanced hexose uptake by IL-3 and IL-5 in male germ cells. Biochem J 381 Pt 2 (2004) 495-501
44. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 1 (1987) 156-159
45. Camporeale G., and Zempleni J. Oxidative folding of interleukin-2 is impaired in flavin-deficient Jurkat cells, causing intracellular accumulation of interleukin-2 and increased expression of stress response genes. J Nutr 133 3 (2003) 668-672
46. Klein B., Rey A., Jourdan M., Donnadieu M.H., and Serrou B. Induction of human T colony formation by phorbol myristate acetate. Scand J Immunol 17 4 (1983) 329-334
47. Kitamura K., Urabe A., Ozawa K., Kimura Y., and Takaku F. Enhancement of human T lymphocyte colony formation by 12-0-tetradecanoylphorbol-13-acetate (TPA). Exp Hematol 11 10 (1983) 1014-1020
48. Foa R., Lusso P., Fierro M.T., Giubellino M.C., Ferrando M.L., and Pegoraro L. Effects of 12-0 tetradecanoyl-phorbol-13-acetate (TPA) on the colony growth of human T lymphocytes. Clin Exp Immunol 56 2 (1984) 377-382
49. Winkelstein A., Simon P.L., Myers P.A., and Weaver L.D. Comparisons of 12-tetradecanoylphorbol-13-acetate (TPA) and PHA as mitogens in the T-lymphocyte colony assay. Exp Hematol 14 11 (1986) 1023-1028
50. Depper J.M., Leonard W.J., Krönke M., Noguchi P.D., Cunningham R.E., Waldmann T.A., et al. Regulation of interleukin 2 receptor expression: effects of phorbol diester, phospholipase C and reexposure to lectin or antigen. J Immunol 133 6 (1984) 3054-3061
51. Sando J.J., Hilfiker M.L., Salomon D.S., and Farrar J.J. Specific receptor for phorbol esters in lymphoid cell populations. Role in enhanced production of T cell growth factor. Proc Natl Acad Sci U S A 78 2 (1981) 1189-1193
52. Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., et al. Cloning of the gamma chain of the human IL-2 receptor. Science 257 5068 (1992) 379-382
53. Misumi Y., Misumi Y., Miki K., Takatsuki A., Tamura G., and Ikehara Y. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem 261 24 (1986) 11398-11403
54. Klausner R.D., Donaldson J.G., and Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol 116 5 (1992) 1071-1080 1992
55. Mansour S.J., Skaug J., Zhao X.H., Giordano J., Scherer S.W., and Melançon P. p200 ARF-GEP1: a Golgi-localized guanine nucleotide exchange protein whose Sec7 domain is targeted by the drug brefeldin A. Proc Natl Acad Sci U S A 96 14 (1999) 7968-7973 1999
56. Claude A., Zhao B.P., Kuziemsky C.E., Dahan S., Berger S.J., Yan J.P., et al. GBF1: a novel Golgi-associated BFA-resistant guanine nucleotide exchange factor that displays specificity for ADP-ribosylation factor 5. J Cell Biol 146 1 (1999) 71-84
57. Henderson D.J., Naya I., Bundick R.V., Smith G.M., and Schmidt J.A. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunology 73 3 (1991) 316-321
58. Khanna A.K. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 70 4 (2000) 690-694
59. Dumont F.J., Staruch M.J., Koprak S.L., Melino M.R., and Sigal N.H. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144 1 (1990) 251-258
60. Henquin J.C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49 11 (2000) 1751-1760
61. Ishihara H., Asano T., Tsukuda K., Katagiri H., Inukai K., Anai M., et al. Pancreatic beta cell line MIN6 exhibits characteristics of glucose metabolism and glucose-stimulated insulin secretion similar to those of normal islets. Diabetologia 36 11 (1993) 1139-1145
62. Miyazaki J., Araki K., Yamato E., Ikegami H., Asano T., Shibasaki Y., et al. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127 (1990) 126-132
63. Tiedge M., Höhne M., and Lenzen S. Insulin secretion, insulin content and glucose phosphorylation in RINm5F insulinoma cells after transfection with human GLUT2 glucose-transporter cDNA. Biochem J 296 Pt1 (1993) 113-118
64. Gazdar A.F., Chick W.L., Oie H.K., Sims H.L., King D.L., Weir G.C., et al. Continuous, clonal, insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. Proc Natl Acad Sci U S A 77 6 (1980) 3519-3523
65. Minami K., Yano H., Miki T., Nagashima K., Wang C.Z., Tanaka H., et al. Insulin secretion and differential gene expression in glucose-responsive and -unresponsive MIN6 sublines. Am J Physiol Endocrinol Metab 279 4 (2000) E773-E781
66. Vigil S.V., de Liz R., Medeiros Y.S., and Fröde T.S. Efficacy of tacrolimus in inhibiting inflammation caused by carrageenan in a murine model of air pouch. Transpl Immunol 19 1 (2008) 25-29
67. Pereira R., Medeiros Y.S., and Fröde T.S. Antiinflammatory effects of tacrolimus in a mouse model of pleurisy. Transpl Immunol 16 2 (2006) 105-111
68. Villarino A.V., Tato C.M., Stumhofer J.S., Yao Z., Cui Y.K., Hennighausen L., et al. Helper T cell IL-2 production is limited by negative feedback and STAT-dependent cytokine signals. J Exp Med 204 1 (2007) 65-71
69. Hubeau C., Le Naour R., Abély M., Hinnrasky J., Guenounou M., Gaillard D., et al. Dysregulation of IL-2 and IL-8 production in circulating T lymphocytes from young cystic fibrosis patients. Clin Exp Immunol 135 3 (2004) 528-534
70. Düfer M., Krippeit-Drews P., Lembert N., Idahl L.A., and Drews G. Diabetogenic effects of cyclosporin Aare mediated by interference with mitochondrial function of pancreatic betacells. Mol Pharmacol 60 4 (2001) 873-879
71. Hoitsma A.J., and Hilbrands L.B. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression. Clin Transplant 20 5 (2006) 659-664
72. Van Duijnhoven E.M., Christiaans M.H., Boots J.M., Nieman F.H., Wolffenbuttel B.H., and Van Hoof J.P. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13 1 (2002) 213-220
73. Kutkuhn B., Hollenbeck M., Heering P., Koch M., Voiculescu A., Reinhard T., et al. Development of insulin resistance and elevated blood pressure during therapy with CsA. Blood Press 6 1 (1997) 13-17
74. Szydlowska K., Zawadzka M., and Kaminska B. Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo. J Neurochem 99 3 (2006) 965-975
75. Oetjen E., Grapentin D., Blume R., Seeger M., Krause D., Eggers A., et al. Regulation of human insulin gene transcription by the immunosuppressive drugs cyclosporin A and tacrolimus at concentrations that inhibit calcineurin activity and involving the transcription factor CREB. Naunyn Schmiedebergs Arch Pharmacol 367 3 (2003) 227-236 2003
76. Redmon J.B., Olson L.K., Armstrong M.B., Greene M.J., and Robertson R.P. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 98 12 (1996) 2786-2793
77. Johnson JD, Ao Z, Ao P, Li H, Dai L, He Z, Tee M, Potter KJ, Klimek AM, Meloche RM, Thompson DM, Verchere CB, Warnock GL, Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets. Cell Transplant. 2009; Apr 10. pii: CT-1977. [Electronic publication ahead of print].
78. Vantyghem M.C., Marcelli-Tourvielle S., Pattou F., and Noël C. Effects of non-steroid immunosuppressive drugs on insulin secretion in transplantation. Ann Endocrinol (Paris) 68 1 (2007) 21-27
79. Hernández-Fisac I., Pizarro-Delgado J., Calle C., Marques M., Sánchez A., Barrientos A., et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets. Am J Transplant 7 11 (2007) 2455-2462
80. Hammond T.G., and Kind C.N. Pancreatic and nephrotoxicity of immunomodulator compounds. Toxicol Lett 82-83 (1995) 99-105
81. Williams D., and Haragsim L. Calcineurin nephrotoxicity. Adv Chronic Kidney Dis 13 1 (2006) 47-55
82. Bennett W.M., DeMattos A., Meyer M.M., Andoh T., and Barry J.M. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 50 4 (1996) 1089-1100
83. Myers B.D., Ross J., Newton L., Luetscher J., and Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 311 11 (1984) 699-705
84. Justo P., Lorz C., Sanz A., Egido J., and Ortiz A. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 14 12 (2003) 3072-3080
85. Yang C.W., Faulkner G.R., Wahba I.M., Christianson T.A., Bagby G.C., Jin D.C., et al. Expression of apoptosis related genes in chronic cyclosporine nephrotoxicity in mice. Am J Transplant 2 5 (2002) 391-399
86. Thomas S.E., Andoh T.F., Pichler R.H., Shankland S.J., Couser W.G., Bennett W.M., et al. Accelerated apoptosis characterizes cyclosporine associated interstitial fibrosis. Kidney Int 53 4 (1998) 897-908
87. Shihab F.S., Andoh T.F., Tanner A.M., Yi H., and Bennett W.M. Expression of apoptosis regulatory genes in chronic cyclosporine nephrotoxicity favors apoptosis. Kidney Int 56 6 (1999) 2147-2159
88. Morales J.M., Andres A., Rengel M., and Rodicio J.L. Influence of cyclosporine, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Review. Nephrol Dial Transplant 16 Suppl 1 (2001) 121-124
89. Donaldson J.G., and Jackson C.L. Regulators and effectors of the ARF GTPases. Curr Opin Cell Biol 12 4 (2000) 475-482
90. Jackson C.L., and Casanova J.E. Turning on ARF: the Sec7 family of guanine-nucleotide exchange factors. Trends Cell Biol 10 2 (2000) 60-67
91. Zhao X., Claude A., Chun J., Shields D., Presley J., and Melançon P. GBF1, a cis-Golgi and VTCs-localized ARF-GEF, is implicated in ER-to-Golgi protein traffic. J Cell Sci 119 Pt18 (2006) 3743-3753
92. Szul T., Garcia-Mata R., Brandon E., Shestopal S., Alvarez C., and Sztul E. Dissection of membrane dynamics of the ARF-guanine nucleotide exchange factor GBF1. Traffic 6 5 (2005) 374-385
93. Manolea F., Claude A., Chun J., Rosas J., and Melancon P. Distinct functions for Arf guanine nucleotide exchange factors at the Golgi complex: GBF1 and BIGs are required for assembly and maintenance of the Golgi stack and trans-Golgi network, respectively. Mol Biol Cell 19 2 (2008) 523-535
94. Grebe M., Gadea J., Steinmann T., Kientz M., Rahfeld J.U., Salchert K., et al. A conserved domain of the Arabidopsis GNOM protein mediates subunit interaction and cyclophilin 5 binding. Plant Cell 12 3 (2000) 343-356
95. Claude A., Zhao B.P., and Melançon P. Characterization of alternatively spliced and truncated forms of the ARF guanine nucleotide exchange factor GBF1 defines regions important for activity. Biochem Biophys Res Commun 303 1 (2003) 160-169
96. San Martin A, Rauch MC, Claude AA, Non catalytic regions of GBF-1 and BIG-1 are essential to their function and localization in the secretory pathway. Biol Res. in press (in revision).